Kathrin Sommer1, Francesco Cottone2, Neil K Aaronson3, Peter Fayers4,5, Paola Fazi2, Gianantonio Rosti6, Emanuele Angelucci7, Gianluca Gaidano8, Adriano Venditti9, Maria Teresa Voso9, Michele Baccarani6, Marco Vignetti2, Fabio Efficace2. 1. Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy. k.sommer@gimema.it. 2. Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy. 3. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 5. European Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. 6. Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Bologna, Italy. 7. Ematologia e Centro Trapianti, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. 8. Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy. 9. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Abstract
PURPOSE: To ensure that observed differences in the scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) reflect actual differences in health-related quality of life (HRQoL) rather than measurement bias, measurement invariance needs to be established. We investigated the assumption of measurement invariance of the EORTC QLQ-C30 in patients with hematological malignancies across age, sex, comorbidity, disease type, and time. METHODS: We used a large database of patients with hematological malignancies, which included HRQoL data collected with the EORTC QLQ-C30. We used the structural equation modeling approach to test for measurement (metric and scalar) invariance across groups (age, sex, comorbidity, disease) and time (baseline, 1 month and 2 month follow-up). Longitudinal invariance was examined in a subgroup of patients diagnosed with myelodysplastic syndromes. RESULTS: Confirmatory factor analyses demonstrated full measurement invariance for age and comorbidity and over time, while support for partial scalar invariance was obtained for sex and disease. Violations of invariance for sex were observed for items of the physical functioning scale and the emotional functioning scale, while for disease type, violations of invariance were observed for items of the physical functioning scale, emotional functioning scale, and the cognitive functioning scale. CONCLUSIONS: Our findings support measurement invariance of the EORTC QLQ-C30 in a large sample of patients with hematological malignancies. The results showed that the number of non-invariant items was negligible, suggesting that this questionnaire is a valid and robust measurement tool in patients with hematological malignancies, also for comparisons across groups and time.
PURPOSE: To ensure that observed differences in the scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) reflect actual differences in health-related quality of life (HRQoL) rather than measurement bias, measurement invariance needs to be established. We investigated the assumption of measurement invariance of the EORTC QLQ-C30 in patients with hematological malignancies across age, sex, comorbidity, disease type, and time. METHODS: We used a large database of patients with hematological malignancies, which included HRQoL data collected with the EORTC QLQ-C30. We used the structural equation modeling approach to test for measurement (metric and scalar) invariance across groups (age, sex, comorbidity, disease) and time (baseline, 1 month and 2 month follow-up). Longitudinal invariance was examined in a subgroup of patients diagnosed with myelodysplastic syndromes. RESULTS: Confirmatory factor analyses demonstrated full measurement invariance for age and comorbidity and over time, while support for partial scalar invariance was obtained for sex and disease. Violations of invariance for sex were observed for items of the physical functioning scale and the emotional functioning scale, while for disease type, violations of invariance were observed for items of the physical functioning scale, emotional functioning scale, and the cognitive functioning scale. CONCLUSIONS: Our findings support measurement invariance of the EORTC QLQ-C30 in a large sample of patients with hematological malignancies. The results showed that the number of non-invariant items was negligible, suggesting that this questionnaire is a valid and robust measurement tool in patients with hematological malignancies, also for comparisons across groups and time.
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Christian Gerlich; Michael Schuler; Matthias Jelitte; Silke Neuderth; Michael Flentje; Markus Graefen; Alexander Krüger; Anja Mehnert; Hermann Faller Journal: Acta Oncol Date: 2016-02-16 Impact factor: 4.089
Authors: Bellinda L King-Kallimanis; Claartje L ter Hoeven; Hanneke C de Haes; Ellen M Smets; Caro C E Koning; Frans J Oort Journal: Qual Life Res Date: 2011-12-23 Impact factor: 4.147
Authors: Johannes M Giesinger; Jacobien M Kieffer; Peter M Fayers; Mogens Groenvold; Morten Aa Petersen; Neil W Scott; Mirjam A G Sprangers; Galina Velikova; Neil K Aaronson Journal: J Clin Epidemiol Date: 2015-09-28 Impact factor: 6.437
Authors: Bradley McGregor; Peter H O'Donnell; Arjun Balar; Daniel Petrylak; Jonathan Rosenberg; Evan Y Yu; David I Quinn; Elisabeth I Heath; Mary Campbell; Zsolt Hepp; Caroline McKay; Joyce Steinberg; Antoine Regnault; Flora Mazerolle; Matthew D Galsky Journal: Eur Urol Date: 2022-02-12 Impact factor: 24.267
Authors: Eleonora Pinto; Alessandro Fabbian; Rita Alfieri; Anna Da Roit; Salvatore Marano; Genny Mattara; Pierluigi Pilati; Carlo Castoro; Marco Cavarzan; Marta Silvia Dalla Riva; Luisa Orrù; Gian Piero Turchi Journal: Behav Sci (Basel) Date: 2022-04-09
Authors: Caterina Calderon; Pere J Ferrando; Urbano Lorenzo-Seva; Estrella Ferreira; Eun Mi Lee; Marta Oporto-Alonso; Berta M Obispo-Portero; Luka Mihic-Góngora; Adan Rodríguez-González; Paula Jiménez-Fonseca Journal: Qual Life Res Date: 2021-12-20 Impact factor: 3.440
Authors: Antoine Regnault; Farrah Pompilus; Anna Ciesluk; Flora Mazerolle; Rafael Bejar; Robert J Fram; Douglas V Faller; Patrick Marquis; Jill A Bell Journal: J Patient Rep Outcomes Date: 2021-07-20